Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer
31 janv. 2022 16h05 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with...
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference
26 janv. 2022 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick...
OcyonBio Appoints Daniel Chang, CPA, MBA, CPMP, CPIM as Chief Financial Officer
25 janv. 2022 09h00 HE
|
OcyonBio (ocyonbio.com)
AGUADILLA, Puerto Rico, Jan. 25, 2022 (GLOBE NEWSWIRE) -- OcyonBio, LLC announces it has appointed Daniel Chang Chief Financial Officer. OcyonBio is creating a contract development and manufacturing...
Global Viral Vectors for Cell Therapy Market Research Report 2022: Demographic Trends, New Developments, Cell and Gene Therapy Advancements, Company Performance Trends, M&As
19 janv. 2022 06h38 HE
|
Research and Markets
Dublin, Jan. 19, 2022 (GLOBE NEWSWIRE) -- The "Viral Vectors Market for Cell Therapy Market: Analysis and Opportunities" report has been added to ResearchAndMarkets.com's offering. All market data...
Global CAR T-cell Therapy Market (2021 to 2031) - Industry Analysis, Size, Share, Growth, Trends, and Forecasts
18 janv. 2022 06h58 HE
|
Research and Markets
Dublin, Jan. 18, 2022 (GLOBE NEWSWIRE) -- The "CAR T-cell Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031" report has been added to...
OcyonBio Appoints Robert Salcedo as Chief Executive Officer
06 janv. 2022 16h00 HE
|
OcyonBio
AGUADILLA, Puerto Rico, Jan. 06, 2022 (GLOBE NEWSWIRE) -- OcyonBio, LLC is creating cell and gene therapy partnership development and manufacturing organization (PDMO). OcyonBio will provide...
Global Cell Therapy Technologies Market to Grow by a CAGR of 13.6% During 2021-2030 and Reach a Revenue of USD 45754.6 Million by 2030; Growing Prevalence of Chronic Diseases Worldwide to Drive Market Growth
06 janv. 2022 07h15 HE
|
Kenneth Research
New York, Jan. 06, 2022 (GLOBE NEWSWIRE) -- According to the statistics by the World Health Organization (WHO), in the year 2020, deaths caused due to cancer registered close to 10 Million....
Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases
05 janv. 2022 07h30 HE
|
Intellia Therapeutics, Inc.
— Intellia grants Kyverna exclusive rights to its differentiated allogeneic cell engineering platform for the development of KYV-201, a next-generation CD19 CAR T-cell therapy to treat autoimmune...
Lyell Immunopharma to Participate in 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 16h05 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (NASDAQ: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with...
Insights on the Translational Regenerative Medicine Global Market to 2026 - Featuring Anika Therapeutics, Celgene and Medipost Among Others
04 janv. 2022 07h28 HE
|
Research and Markets
Dublin, Jan. 04, 2022 (GLOBE NEWSWIRE) -- The "Translational Regenerative Medicine Market Research Report by Product Type, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of...